Using biologics safely by Choy, Ernest H.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/122194/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Choy, Ernest H. 2019. Using biologics safely. Rheumatology 58 (9) , pp. 1515-1516.
10.1093/rheumatology/kez129 file 
Publishers page: http://dx.doi.org/10.1093/rheumatology/kez129
<http://dx.doi.org/10.1093/rheumatology/kez129>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
Using	Biologics	Safely	1	
Ernest	H	Choy.	2	
	3	
CREATE	Centre,	Section	of	Rheumatology,	Division	of	Infection	and	Immunity,	Cardiff	4	
University,	Cardiff,	UK	5	
	6	
Correspondence:	Professor	Ernest	Choy,	CREATE	Centre,	Section	of	Rheumatology,	Division	7	
of	Infection	and	Immunity,	Cardiff	University	School	of	Medicine,	Cardiff	University,	Cardiff,	8	
UK	CF14	4XN.	Email:	choyeh@cardiff.ac.uk	9	
	10	
	 	11	
This	year	marks	the	20
th
	anniversary	of	the	first	biologic	Disease	Modifying	Anti-Rheumatic	1	
Drug	(bDMARD),	infliximab,	a	tumour	necrosis	factor	inhibitor,	approved	for	the	treatment	2	
of	rheumatoid	arthritis	(RA).	It	heralds	two	decades	of	“targeted”	treatments	for	3	
inflammatory	arthritis	with	seven	classes	of	biologic	DMARDs	(bDMARDs)	plus	target	4	
synthetic	DMARDs	(tsDMARDs):	the	janus	kinase	inhibitors.	They	have	transformed	the	5	
outcome	of	inflammatory	arthritis	with	millions	of	patients	having	been	treated	globally.	6	
Their	therapeutic	benefit	is	indisputable.	However,	bDMARDs	are	potent	7	
immunosuppressive	agents	associated	with	significant	risk	of	potentially	serious	side	effects.	8	
Clinical	vigilance	is	necessary	to	maximize	benefit	and	mitigate	against	the	risk	of	serious	9	
complications.	To	this	end,	the	British	Society	for	Rheumatology	and	British	Healthcare	10	
Professional	for	Rheumatology	have	produced	new	guidelines	on	bDMARD	safety	in	11	
inflammatory	arthritis
1
	based	on	a	large	systematic	review.	It	supersedes	previous	12	
guidelines	on	tumour	necrosis	factor	(TNF)	inhibitors
2
,	rituximab
3
	and	tocilizumab
4
	for	RA.	13	
The	new	guidelines	included	patients	with	psoriatic	arthritis	(PsA)	and	axial	spondyloarthritis	14	
(SpA)	as	well	as	the	bDMARDs:	abatacept	and	ustekinumab.	However,	they	only	apply	to	15	
adult	patients	and	exclude	biologics	approved	by	NICE	after	June	2016	(secukinumab	and	16	
sarilumab),	tsDMARDs	and	biosimilars.	It	also	does	not	cover	safety	in	the	context	of	17	
pregnancy	and	breastfeeding,	which	has	been	addressed	by	separate	guidelines
5
.	18	
	19	
There	are	several	important	differences	between	the	new	and	previous	guidelines.	20	
Regarding	infection,	the	new	guideline	recommended	using	etanercept	or	abatacept	as	a	21	
first	line	biological	therapy	in	patients	at	high	risk	of	infection	and	stated	that	the	risk	of	22	
tuberculosis	(TB)	reactivation	is	higher	with	anti-TNF	monoclonal	antibodies	(notably	23	
adalimumab	and	infliximab)	than	for	etanercept.	If	patients	require	anti-TNF	therapy	and	24	
have	a	high	risk	of	TB	reactivation,	etanercept	is	preferred.	Furthermore,	these	high-risk	25	
patients	should	be	reviewed	every	3	months.	The	guidelines	on	assessing	and	management	26	
of	these	patients	are	in	part	based	on	the	“2005	British	Thoracic	Society	recommendations	27	
on	assessing	risk	and	for	managing	Mycobacterium	tuberculosis	infection	and	disease	in	28	
patients	due	to	start	anti-TNF-α	treatment”
	6
.	The	definition	of	“high	risk”	was	based	on	the	29	
incidence	of	tuberculosis	in	England	and	Wales.	Given	the	data	were	more	than	10	years	30	
old,	an	update	would	have	been	helpful.	The	guideline	committee	considered	that	relatively	31	
few	large	long-term	studies	have	examined	the	risk	of	TB	reactivation	in	non-TNF	inhibitor	32	
biologics,	so	cautiously	advised	Rheumatologists	to	follow	the	TB	screening	practice	as	for	33	
anti-TNF	agents	but	noted	that	the	incidence	of	TB	reactivation	for	abatacept,	rituximab	and	34	
tocilizumab,	is	low.	Reactivation	of	varicella	zoster	(shingles)	is	a	risk	associated	with	janus	35	
kinase	inhibitors	although	it	has	been	reported	also	in	patients	treated	by	biologic	agents.	In	36	
patients	without	a	past	history	of	chickenpox,	confirmed	by	a	negative	varicella	zoster	virus	37	
antibody	test,	the	new	guideline	recommend	varicella	zoster	vaccination	should	be	offered	38	
prior	to	biologic	treatment	unless	there	are	contraindications	such	as	concurrent	high	dose	39	
prednisolone,	methotrexate	or	azathioprine.	However,	if	the	patient	did	not	receive	zoster	40	
vaccination	and	has	been	exposed	to	primary	varicella	infection,	prophylaxis	with	varicella	41	
zoster	immune	globulin	should	be	considered	if	the	risks	from	infection	are	perceived	to	be	42	
significant.	43	
	44	
Regarding	malignancy,	the	committee	reckoned	that	there	is	no	conclusive	evidence	for	an	45	
increased	risk	of	solid	tumours	or	lymphoproliferative	disease	linked	with	biologic	therapy.	46	
However,	there	is	a	potential	association	between	non-melanotic	skin	cancers	with	anti-TNF	47	
therapy,	hence	advice	on	the	need	for	preventative	skin	care,	skin	surveillance	and	prompt	1	
reporting	of	new	persistent	skin	lesions.	In	patients	who	have	had	prior	treatment	with	>150	2	
PUVA	and/or	>350	UVB	phototherapy,	the	new	guideline	recommended	discussion	with	a	3	
dermatologist	prior	to	commencing	anti-TNF	therapy.	This	information	may	not	be	readily	4	
available	to	the	Rheumatology	team.	However,	in	the	biologic	era,	patients	are	less	likely	to	5	
be	treated	with	high	dose	phototherapy.			6	
	7	
Managing	RA	patients	with	interstitial	lung	disease	(ILD)	is	challenging,	the	available	8	
evidence	is	limited	and	conflicting.	The	new	guideline	emphasized	that	interstitial	lung	9	
disease	is	not	an	absolute	contraindication	to	biological	therapy.	However,	in	patients	with	10	
poor	respiratory	reserve,	consulting	a	respiratory	physician	with	a	specialist	interest	in	ILD	11	
would	be	advisable.	All	patients	with	ILD	receiving	biologic	therapy	should	be	jointly	12	
managed	with	a	respiratory	physician	and	have	regular	monitoring	of	pulmonary	function.	13	
The	new	guideline	recommended	stopping	biological	therapy	in	patients	with	worsening	or	14	
new	features	of	ILD.	The	committee	recommended	rituximab	or	abatacept	may	be	15	
considered	first-line	biologic	in	patients	with	ILD.	16	
	17	
Since	the	publication	of	previous	guidelines,	adalimumab	has	been	approved	by	the	Food	18	
and	Drug	Administration	and	European	Medicine	Agency	for	the	treatment	of	non-19	
infectious	uveitis.	In	the	new	guideline,	adalimumab	and	infliximab	have	been	20	
recommended	as	preferred	anti-TNF	therapy	in	patients	with	uveitis.	However,	uveitis	has	21	
been	reported	following	anti-TNF	therapy	especially	after	etanercept	treatment
7
.	22	
	23	
For	patients	scheduled	for	surgery,	the	guideline	highlighted	that	there	is	a	balance	between	24	
the	risk	of	perioperative	disease	flare	versus	the	risk	of	infection	and	wound	healing.	The	25	
latter	is	dependent	on	the	surgical	procedure.	For	low-risk	procedures,	a	gap	of	one	dosing	26	
interval	is	recommended.	For	higher	risk	procedures,	stopping	biologic	agent	3-5	half-lives	27	
before	surgery	is	recommended.	One	assumes	that	this	will	also	apply	to	patients	at	high	28	
risk	of	infection.	For	patients	receiving	rituximab,	the	recommended	interval	is	3-6	months	29	
prior	to	surgery.	Whilst	for	patients	receiving	tocilizumab,	the	interval	should	be	4	weeks	for	30	
intravenous	treatment	and	two	weeks	for	subcutaneous	therapy.		31	
	32	
The	guideline	committee	should	be	congratulated	on	these	recommendations	based	on	a	33	
comprehensive	review	of	the	evidence.	Furthermore,	these	guidelines	differ	from	other	34	
systematic	reviews	such	as	published	by	EULAR
8
	in	that	practical	recommendations	on	35	
choice	of	biologic	is	given	such	as	rituximab	and	abatacept	in	patients	with	ILD.	The	36	
challenge	for	the	committee	is	to	update	these	guidelines	to	include	new	treatments	in	a	37	
timely	fashion.	Perhaps	the	committee	can	also	consider	making	recommendations	on	38	
practical	clinical	issues	such	as:	should	the	same	screening	be	performed	in	biologics	naïve	39	
patients	versus	patients	switching	biologic	treatment.	Furthermore,	registries	have	found	40	
that	patients	with	multiple	comorbidities	are	at	risk	of	side	effects	from	biologic	treatment.	41	
How	can	these	at	high	risk	be	identified	in	clinical	practice?	Should	monitoring	and	42	
treatment	be	different	in	these	high-risk	patients?	43	
	44	
	45	
	46	
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